Sign in
Taking people in South KoreaPhase 3

Single drugs versus a combination pill in hypertension and type 2 diabetes

Compares single drugs with HL1113 in hypertension and type 2 diabetes.

Key facts

Who runs it
Hanlim Pharm. Co., Ltd.
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
Status
Recruiting
Phase
Phase 3
People taking part
228 people, planned
Started
18 Dec 2025
Expected to end
Dec 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Test group
  • Exploratory test group
  • Control group 1
  • Control group 2
Record updated
27 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who have both essential hypertension (high blood pressure) and type 2 diabetes. It compares single-drug treatment with a fixed-dose combination.

Age
19 years or older
Sex
Women and men can join.
Disease stage
Essential hypertension together with type 2 diabetes mellitus.

Main reasons for not taking part

  • Diastolic blood pressure (MSDBP) of 110 mmHg or more in the selected arm at both screening and randomization
  • A difference of 20 mmHg or more in systolic blood pressure, or 10 mmHg or more in diastolic blood pressure, between the two arms at screening

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Adult male or female subjects aged ≥19 years at the time of written informed consent
  • Subjects diagnosed with essential hypertension accompanied by type 2 diabetes mellitus
  • etc

Who cannot take part

  • Subjects whose blood pressure measured in the selected arm at both screening and randomization meets the following criterion: MSDBP ≥ 110 mmHg
  • Subjects whose blood pressure measured three consecutive times in each arm at intervals of at least 2 minutes at screening shows a difference of ≥20 mmHg in SBP and ≥10 mmHg in DBP
  • etc

Where in South Korea

  • The Catholic University of Korea Bucheon St.Mary's HospitalSeoul, South KoreaContact: LimTaking people

About the trial

What the trial wants to find out

This clinical trial is a randomized, active controlled, double blind, parallel, multi center, phase 3 study to evaluate the efficacy and safety of monotherapy group of HL1113R1 or HL1113R2 versus HL1113 (Fixed dose combination) in patients with essential hypertension and type II diabetes mellitus

The 4 groups in the trial

  • Test groupTreatment being tested
  • Exploratory test groupTreatment being tested
  • Control group 1Placebo, for comparison
  • Control group 2Placebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Active Controlled, Double Blind, Parallel, Multi Center, Phase 3 Study to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
Plain-language title
Single drugs versus a combination pill in hypertension and type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
27 April 2026